We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: real‑world evidence
MedXY News
EnglishTag

real‑world evidence

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity
Diabetes & Endocrinologyreal‑world evidencehealth disparities

Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity

By MedXY|Sep 11, 2026

A significant proportion of real-world diabetic macular edema patients are excluded from clinical trials of anti-VEGF therapy due to stringent systemic criteria, disproportionately affecting racial minorities. This study highlights the need

Response Kinetics Following CAR T-Cell Therapy for Large B-Cell Lymphoma: Insights from the LYSA DESCAR-T Registry
Clinical Updatesreal‑world evidence
response kinetics

Response Kinetics Following CAR T-Cell Therapy for Large B-Cell Lymphoma: Insights from the LYSA DESCAR-T Registry

By MedXY|Aug 24, 2026

This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from parti

Glucose in Motion: Insights into Temporal Patterns of Glycemic Control in Real-World Diabetes Management
Clinical Updatesreal‑world evidenceGlycemic Control

Glucose in Motion: Insights into Temporal Patterns of Glycemic Control in Real-World Diabetes Management

By MedXY|Aug 18, 2026

This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights
Clinical Updatesreal‑world evidenceJAK inhibitors

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights

By MedXY|Aug 17, 2026

This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl

Harnessing Real-World Evidence to Optimize GLP-1-Based Therapies: Insights from a NIDDK Workshop
Diabetes & EndocrinologydiabetesGLP-1 receptor agonists

Harnessing Real-World Evidence to Optimize GLP-1-Based Therapies: Insights from a NIDDK Workshop

By MedXY|Jul 7, 2026

A NIDDK workshop highlighted the crucial role of real-world evidence in addressing gaps about GLP-1 receptor agonists’ safety, effectiveness, adherence, and economic impact to improve clinical and regulatory decision-making.

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
newsreal‑world evidenceplatelet monitoring

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

By MedXY|Aug 18, 2026

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation

Superior Efficacy of Cenobamate in Drug-Resistant Focal Epilepsy: Real-World Evidence
NeurologyCenobamatedrug-resistant focal epilepsy

Superior Efficacy of Cenobamate in Drug-Resistant Focal Epilepsy: Real-World Evidence

By MedXY|Apr 29, 2026

This article reviews a large real-world study demonstrating cenobamate’s superior effectiveness over brivaracetam, lacosamide, and perampanel in reducing seizures for adults with drug-resistant focal epilepsy.

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes
Cardiologycardiovascular outcomescomparative effectiveness

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

By MedXY|Apr 18, 2026

A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful

Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes
newsEndometrial Cancermolecular biomarkers

Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes

By MedXY|Apr 9, 2026

A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-en

Real-World Evidence Confirms Burosumab Effectiveness Across All Ages in X-linked Hypophosphatemia
Diabetes & EndocrinologyBurosumabFGF23

Real-World Evidence Confirms Burosumab Effectiveness Across All Ages in X-linked Hypophosphatemia

By MedXY|Apr 6, 2026

A 3-year prospective study demonstrates sustained biochemical and clinical improvements with burosumab in XLH patients across pediatric and adult age groups, including those typically excluded from clinical trials.

Treatment Evolution in 5q-Spinal Muscular Atrophy: Real-World Evidence and Clinical Insights from the SMArtCARE Registry
Clinical Updatesgene therapyreal‑world evidence

Treatment Evolution in 5q-Spinal Muscular Atrophy: Real-World Evidence and Clinical Insights from the SMArtCARE Registry

By MedXY|Mar 8, 2026

This review analyzes the shifting landscape of SMA therapy using data from 2,140 patients, highlighting the transition between nusinersen, risdiplam, and onasemnogene abeparvovec and the factors driving treatment switches.

Cenobamate Outperforms Brivaracetam, Lacosamide, and Perampanel in Real-World Focal Epilepsy Management
Neurologyantiseizure medicationsCenobamate

Cenobamate Outperforms Brivaracetam, Lacosamide, and Perampanel in Real-World Focal Epilepsy Management

By MedXY|Feb 10, 2026

A large multicenter real-world study indicates that cenobamate provides superior effectiveness and seizure freedom rates compared to brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy, despite a higher inc

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns
newsCancer survivaloncology

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

By MedXY|Feb 7, 2026

A large-scale federated study of 1.7 million European patients highlights significant variations in cancer survival and comorbidity profiles, emphasizing the role of real-world data and the OMOP-CDM framework in benchmarking oncological out

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
CardiologyExtended TherapyOral Anticoagulation

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

By MedXY|Nov 22, 2025

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities